Action Pharma A/S is a biopharmaceutical company founded in 2000 and located in Denmark with offices and laboratories in Aarhus and Copenhagen.
Action Pharma is dedicated to the discovery and development of novel drugs that can significantly improve the therapy of inadequately treated cardiovascular diseases. The core therapeutic focus of our company is obesity, Type II diabetes / metabolic syndrome, inflammatory diseases, organ protection in severe cardiovascular diseases such as myocardial infarction, and post-surgical organ dysfunction.
Our technology and drug development platform coupled with our strong patent portfolio gives the company a unique competitive position.
Our main strategy is to bring compounds rapidly from pre-clinical development into clinical trials for subsequent partnering. The goal is to bring one compound into clinical development per year and currently two lead candidates are in clinical development. We plan to seek partners for late clinical development and commercialisation of our drug candidates after successful development in phase I or II by partnering with major biotech and pharmaceutical companies.